AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aktis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $835.58M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $3.40M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | During market hours | $3.20M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | During market hours | – | – | – |
Press releases
Announcements Aktis Oncology filed with the SEC
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K